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Abstract
Background: New-onset atrial fibrillation (NeOAF) is a common type of tachyarrhythmia in critically ill patients and
is associated with increased mortality in patients with sepsis. However, the prognostic impact of restored sinus
rhythm (SR) in septic patients with NeOAF remains unclear.
Methods: A total of 791 patients with sepsis, who were admitted to a medical intensive care unit from January
2011 to January 2014, were screened. NeOAF was detected by continuous electrocardiographic monitoring. Patients
were categorized into three groups: no NeOAF, NeOAF with restored SR (NeOAF to SR), and NeOAF with failure to
restore SR (NeOAF to atrial fibrillation (AF)). The endpoint of this study was in-hospital mortality. Patients with pre-
existing AF were excluded.
Results: We reviewed the data of 503 eligible patients, including 263 patients with no NeOAF and 240 patients
with NeOAF. Of these 240 patients, SR was restored in 165 patients, and SR could not be restored in 75 patients.
The NeOAF to AF group had the highest in-hospital mortality rate of 61.3% compared with the NeOAF to SR and
no NeOAF groups (26.1% and 17.5%, respectively). Moreover, multivariate logistic regression analysis revealed that
failure of restored SR was independently associated with increased in-hospital mortality in patients with sepsis and
NeOAF.
Conclusions: Failure to restore a sinus rhythm in patients with new-onset atrial fibrillation may be associated with
increased in-hospital mortality in patients with sepsis. Further prospective studies are needed to clarify the effects of
restoration of sinus rhythm on survival in patients with sepsis and new-onset atrial fibrillation.
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Background
Atrial fibrillation (AF) is the most common sustained car-
diac arrhythmia in critically ill patients [1, 2]. In past de-
cades, increased attention has been paid to new-onset
atrial fibrillation (NeOAF) in patients undergoing cardiac
or noncardiac surgery, patients with major trauma,
and critically ill patients, and it is associated with
poor prognosis [3–10].
Sepsis, a potentially life-threatening organ dysfunction
syndrome caused by a dysregulated host response to in-
fection, is one of the leading causes of death worldwide.
On the basis of disease severity, it can be categorized
into sepsis and septic shock. Septic shock is defined by
requirement for vasopressors to maintain a mean arterial
pressure of 65 mmHg or greater and serum lactate level
greater than 2 mmol/L in the absence of hypovolemia
[11–13]. In recent studies, NeOAF has been shown to
be prevalent in patients with sepsis and to be associated
with longer hospital stay and increased morbidity and
mortality [14–24].
A longer AF burden leads to worsening cardiac effects
and makes sepsis treatment more difficult. A previous
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study found that management with electrical cardiover-
sion or pharmacological treatment for NeOAF may im-
prove outcomes in critically ill patients [18]. It remains
unclear whether restored sinus rhythm (SR) in patients
with sepsis and NeOAF is associated with favorable
prognosis. Therefore, among patients with sepsis, this
study investigated the impact on in-hospital mortality of
restoration of SR in patients with NeOAF in comparison




This single-center, retrospective, comparative cohort
study was conducted at Tri-Service General Hospital,
National Defense Medical Center, and involved screen-
ing of consecutive adults who were admitted to a
medical intensive care unit (ICU) with a diagnosis of sep-
sis or septic shock from January 2011 to January 2014.
The institutional review board of the center approved the
study with a protocol number of 2-104-05-003. Informed
consent was waived due to the observational design.
Previous medical records and a 12-lead electrocardio-
gram (ECG) were fully evaluated by chart review. Pre-
existing AF and arrhythmia other than AF were excluded
initially. Then, individuals meeting any of the following
criteria were excluded: (1) age older than 90 years; (2)
ICU stay less than 3 days; (3) missing or incomplete
clinical data or ECG; or (4) major surgery within 2 weeks
prior to this admission. A flowchart of the enrollment of
the study population is shown in Fig. 1.
Medical records were reviewed to collect information
on baseline characteristics including demographic data,
laboratory parameters, and the underlying comorbidities
of hypertension, diabetes mellitus (DM), coronary artery
disease (CAD), heart failure, cerebrovascular disease
(CVD), chronic obstructive pulmonary disease (COPD),
chronic kidney disease (CKD), and prior thyroid disease.
Prior medication use, including beta-blockers or non-
dihydropyridine calcium channel blockers (non-DHP
CCBs) was evaluated. Transthoracic echocardiographic
findings were assessed on ICU admission with a focus on
left atrium diameter (LAD), left ventricular end-diastolic
dimension (LVEDD), left ventricular end-systolic dimen-
sion (LVESD), and left ventricular ejection fraction
(LVEF).
Diagnosis of sepsis and its severity
Sepsis and septic shock were defined based on the The
Third International Consensus Definitions for Sepsis
and Septic shock (Sepsis-3) [13]. The management of
sepsis was based on early goal-directed therapy recom-
mended in the guidelines of the Surviving Sepsis
Campaign [11, 12].
According to Surviving Sepsis Campaign recommen-
dations, information on infection sites and sepsis-
induced acute organ dysfunction, including neurologic,
circulatory, respiratory, renal, hepatic, and hematologic
dysfunction was collected. Scores of severity-of-disease
classification systems including the Acute Physiology
and Chronic Health Evaluation II (APACHE II) and
Sequential Organ Failure Assessment (SOFA) were re-
corded for each individual on ICU admission [25, 26].
Detection and management of NeOAF
During ICU admission, all patients received continuous
electrocardiographic monitoring. The 12-lead ECGs
were obtained when deemed clinically appropriate by
the critical care team. The diagnosis of AF, defined as
the absence of P waves and irregular ventricular activity
lasting for more than 30 seconds, was confirmed by
clinicians. After NeOAF was detected, the decision of
electrical cardioversion, pharmacological treatment, or a
wait-and-see strategy for NeOAF was made by the re-
sponsible clinicians based on the patient’s hemodynamic
status and contraindication for antiarrhythmic agents.
Failure to restore SR in patients with NeOAF was de-
fined as persistent or recurrent AF 7 days after the onset
of NeOAF and was referred to as NeOAF to AF. The
restoration of SR in patients with NeOAF is referred to
as NeOAF to SR. Patients with NeOAF who died within
7 days after admission was categorized as the indicated
group based on the final rhythm before death. The end-
point of this study was in-hospital mortality, which was
confirmed by records of the death note.
Statistical analyses
Statistical analyses were performed using the SPSS soft-
ware package (version 17.0; SPSS, Chicago, IL, USA),
Fig. 1 Patients with sepsis were enrolled and categorized into groups
based on the occurrence of atrial fibrillation (AF) and AF status during
ICU stay from January 2011 to January 2014. ECG electrocardiogram, SR
sinus rhythm, NeOAF new-onset atrial fibrillation
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and differences were considered statistically significant
when the P value was <0.05. Continuous variables are
presented as mean and standard deviation. Categorical
variables are presented as the number of patients and
the corresponding percentage. The differences in the
characteristics of the groups were assessed using the un-
paired two-tailed Student t test or one-way analysis of
variance (ANOVA) for continuous variables and the chi-
square and Fisher exact tests for nominal variables.
The significant variables (P < 0.05) associated with the
individual AF status in patients were identified. Back-
ward stepwise logistic regression analysis was conducted
to evaluate the significant predictors of NeOAF and
NeOAF to AF. To evaluate the association between the
NeOAF status and in-hospital mortality, we constructed
two regression models. Model 1 was the univariate logis-
tic regression analysis of the AF status. Model 2 was the
multivariate logistic regression analysis after adjustment
for significant confounding factors, which were selected
based on the criteria of being associated with exposure,
associated with outcomes, and not intermediate variables
between exposure and outcome [27]. A Cox propor-
tional hazard model with time-varying exposure was
constructed to confirm the associations between individ-
ual AF status and in-hospital mortality.
Results
Study population and incidence of NeOAF
A total of 791 patients were screened. Of these patients,
36 and 43 patients were excluded due to pre-existing AF
and arrhythmia other than AF, respectively. The preva-
lence of pre-existing AF was 4.5% (36/791). The
incidence of NeOAF was 35.1% (265/755). After exclud-
ing patients older than 90 years, with less than 3 days of
ICU stay, missing or incomplete data, or having had
major surgery within 2 weeks of sepsis, 503 eligible pa-
tients were evaluated based on the different AF status.
Among these, 263 patients had no AF and 240 patients
developed NeOAF after ICU admission. SR was restored
in 165 patients (NeOAF to SR) and SR could not be re-
stored in 75 patients (NeOAF to AF) as shown in Fig. 1.
Baseline characteristics of patients with sepsis and
different AF status
The baseline characteristics of patients with sepsis and
different AF status are compared in Table 1. Patients in
the NeOAF to SR and NeOAF to AF groups were sig-
nificantly older than those in the no NeOAF group.
Moreover, a higher prevalence of hypertension, heart
failure, CAD, and CVD was observed in patients with
NeOAF compared with those without NeOAF. No sig-
nificant differences were observed in COPD, DM,
uremia, and thyroid disorder between these three
groups. Regarding prior medication use before ICU ad-
mission, patients with the NeOAF to AF group had
lower beta-blocker use compared with those with the
NeOAF to SR group.
Table 2 shows the laboratory and echocardiographic
results in patients with sepsis and different AF status.
All the laboratory data and examinations were per-
formed at the beginning of ICU admission. No statisti-
cally significant differences were observed in serum
white blood cell (WBC) count, electrolytes, albumin, or
B-type natriuretic peptide (BNP) levels among the three
Table 1 Baseline characteristics of patients with sepsis and different AF status
Characteristics Overall patients (n = 503) P value
No NeOAF (n = 263) NeOAF to SR (n = 165) NeOAF to AF (n = 75)
Age, years 69.5 ± 15.6 77.8 ± 10.3† 76.2 ± 11.0a <0.01
Male, n (%) 174 (66.2) 90 (54.5)† 46 (61.3) 0.06
Comorbidities, n (%)
Hypertension 145 (55.1) 111 (67.3)† 44 (58.7) 0.04
Heart failure 25 (9.5) 35 (21.2)† 15 (20.0)a <0.01
Coronary artery disease 90 (34.2) 70 (42.4) 37 (49.3)a 0.04
Cerebrovascular disease 56 (21.3) 53 (32.1)† 23 (30.7) 0.03
COPD 52 (19.8) 28 (17.0) 12 (16.0) 0.66
Diabetes mellitus 97 (36.9) 65 (39.4) 21 (28.0) 0.23
Uremia 18 (6.8) 17 (10.3) 9 (12.0) 0.26
Thyroid disorder 10 (3.8) 10 (6.1) 6 (8.0) 0.29
Prior medication, n (%)
Beta blocker 29 (11.0) 27 (16.4) 4 (5.3)b 0.04
Calcium channel blocker 9 (3.4) 10 (6.1) 2 (2.7) 0.32
COPD chronic obstructive pulmonary disease, AF atrial fibrillation, NeOAF new-onset atrial fibrillation. SR sinus rhythm. aP < 0.05 vs. no NeOAF. bP < 0.05 vs. NeOAF
to SR
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groups. However, C-reactive protein (CRP) was lowest in
the NeOAF to SR group than in the no NeOAF and
NeOAF to AF groups (10.0 ± 9.9, 12.8 ± 10.9 and 11.2 ±
8.5 mmol/L, respectively). Troponin-I was highest in the
NeOAF to AF group than in the no NeOAF and NeOAF
to SR groups. On echocardiography, both the NeOAF to
SR and NeOAF to AF group had a larger left atrial diameter
than the no NeOAF group. Left ventricular systolic dysfunc-
tion was more prevalent in patients with NeOAF to AF.
Sepsis severity in patients with different AF status
The most common infection site of sepsis in our study
population was the respiratory tract, followed by the
urinary tract and intra-abdominal sites (Table 3). Pa-
tients with NeOAF had significantly high SOFA and
APACHE II scores, which are severity indices of sepsis.
The no NeOAF, NeOAF to SR, and NeOAF to AF
groups had SOFA scores of 7.0 ± 3.2, 7.6 ± 3.0, and 9.3 ±
3.2 and APACHE II scores of 21.6 ± 5.5, 22.8 ± 5.8, and
24.6 ± 6.1, respectively. Dopamine and norepinephrine
were more commonly used in the NeOAF to AF group.
Management of NeOAF in patients with sepsis
We reviewed 240 eligible patients with NeOAF. Among
these 240 patients, SR was restored in 165 patients
(NeOAF to SR), and SR could not be restored in 75 pa-
tients (NeOAF to AF). Treatments received by patients
with NeOAF are shown in Table 4. Beta-blockers
(36.7%) and amiodarone (33.3%) were the most com-
monly used in patients with NeOAF and sepsis, followed
by non-DHP CCBs and digitalis glycosides. Electrical
cardioversion was performed in only eight patients.
There were no significant differences in pharmacological
therapies and electrical cardioversion between the
NeOAF to SR and NeOAF to AF groups.
Clinical impact of rhythm control in patients with sepsis
and NeOAF
Patients with sepsis and NeOAF had a longer ICU stay
(NeOAF to SR group: 16.7 ± 13.6; NeOAF to AF group:
17.3 ± 23.3 days) than those without NeOAF (11.4 ±
11.1 days). Moreover, the NeOAF to AF group had the
highest in-hospital mortality rate of 61.3% (46/75) com-
pared with the rate of 26.1% (43/165) in the NeOAF to
SR group and of 17.5% (46/263) in the no NeOAF group
(P < 0.01) as shown in Fig. 2.
Based on the data in Tables 1, 2, 3, and 4, the significant
variables were selected associated with different AF status
as follows: age; hypertension; heart failure; CAD; CVD;
prior beta-blocker use; CRP; Troponin-I; LA dimension;
LVEF; SOFA scores; APACHE II scores; neurological,
circulation, or hepatic failure; renal dysfunction; dopamine
use; and norepinephrine use. The logistic regression models
were constructed to analyze the singificant predictors of
NeOAF and NeOAF to AF in patients with sepsis. For all
patients with NeOAF, these predictors included age, heart
failure, CVD, and SOFA scores. For patients with NeOAF
to AF, these predictors included age, LA dimension,
APACHE II scores, hepatic dysfunction, dopamine use,
and norepinephrine use.
Regarding the association between different AF status
and in-hospital mortality, the univariate logistic regression
Table 2 Laboratory findings and echocardiography index at admission in patients with sepsis and different AF status
Overall patients (n = 503) P value
No NeOAF (n = 263) NeOAF to SR (n = 165) NeOAF to AF (n = 75)
Laboratory
WBC (×103/L) 13.47 ± 8.73 13.43 ± 7.23 15.39 ± 11.73 0.22
CRP (mmol/L) 12.8 ± 10.9 10.0 ± 9.9† 11.2 ± 8.5 0.02
Na+ (mmol/L) 135.6 ± 8.5 135.7 ± 10.1 136.7 ± 7.8 0.64
K+ (mmol/L) 4.1 ± 1.0 4.2 ± 1.0 4.1 ± 0.9 0.46
Free Ca2+ (mmol/L) 4.23 ± 0.31 4.35 ± 0.46 4.17 ± 0.68 0.46
Albumin (g/dL) 2.7 ± 0.6 2.7 ± 0.6 2.6 ± 0.6 0.37
BNP (pg/ml) 918.6 ± 1152.2 1131.3 ± 1325.6 1102.4 ± 1418.1 0.58
Tr-I (ng/ml) 1.09 ± 5.92 1.98 ± 5.95 3.71 ± 13.42a 0.04
Echocardiography
LAD (mm) 36.5 ± 7.4 38.4 ± 7.2† 40.5 ± 7.2a <0.01
LVEDD (mm3) 45.7 ± 8.0 46.1 ± 7.7 46.6 ± 7.5 0.73
LVESD (mm3) 30.3 ± 8.0 30.9 ± 7.3 32.3 ± 8.4 0.22
LVEF < 50%, n (%) 31 (13.7) 29 (18.2) 18 (27.7)† 0.03
NeOAF new-onset atrial fibrillation, AF atrial fibrillation, SR sinus rhythm, WBC white blood cell count, CRP C-reactive protein, BNP B-type natriuretic peptide, Tr-I
troponin I, LAD left atrium diameter, LVEDD left ventricular end diastolic diameter, LVESD left ventricular end systolic diameter, LVEF left ventricular ejection
fraction. aP < 0.05 vs. no NeOAF
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analysis showed that NeOAF to AF was significantly
associated with increased in-hospital mortality com-
pared to NeOAF to SR and no NeOAF (OR = 4.50,
95% CI = 2.52–8.04; P < 0.01 and OR = 7.48, 95% CI
= 4.26–13.14; P < 0.01) (Table 5). The multivariate logis-
tic regression analysis, which was adjusted for the significant
confounding factors including: age; CAD; LVEF; SOFA
scores; neurological, circulation, hepatic, or renal dysfunc-
tion; and dopamine and norepinephrine use, revealed that
NeOAF to AF itself was an independent risk factor for in-
hospital mortality in patients with sepsis compared to
NeOAF to SR and no NeOAF (OR= 2.22, 95% CI = 1.02–
4.83; P < 0.05 and OR= 3.31, 95% CI = 1.54–7.13; P < 0.01).
Moreover, Cox proportional hazard models were applied to
examine the association between different AF status and in-
hospital mortality. There were some differences compared
with the logistic regression model, especially in the associ-
ation between NeOAF to AF or no NeOAF and in-hospital
mortality (Additional file 1: Table S1). However, the associa-
tions between NeOAF to AF or NeOAF to SR and in-
hospital mortality were similar (P < 0.05).
Discussion
Main findings
In this study, we demonstrated that NeOAF in patients
with sepsis was associated with an increased risk of in-
Table 3 Disease severity index of sepsis in patients with various AF statuses
Overall patients (n = 503) P value
No NeOAF (n = 263) NeOAF to SR (n = 165) NeOAF to AF (n = 75)
Infection site, n (%)
Respiratory tract 168 (63.9) 112 (67.9) 48 (64.0)
Urinary tract 57 (21.7) 35 (21.2) 14 (18.7)
Gastrointestinal 23 (8.7) 9 (5.5) 5 (6.7)
Others 15 (5.7) 9 (5.5) 8 (10.7)
SOFA score 7.0 ± 3.2 7.6 ± 3.0 9.3 ± 3.2bc <0.01
APACHE II score 21.6 ± 5.5 22.8 ± 5.8 24.6 ± 6.1b <0.01
Total organ failurea, n 2 (1–3) 2 (1–3) 3 (2–4)
Neurologic failure 87 (33.1) 49 (29.7) 39 (52.0)bc <0.01
Circulatory failure 118 (44.9) 82 (49.7) 57 (76.0)bc <0.01
Respiratory failure 229 (87.1) 150 (90.9) 71 (94.7) 0.13
Hepatic failure 8 (3.0) 4 (2.4) 8 (10.7)bc <0.01
Renal failure 86 (32.7) 65 (39.4) 39 (52.0)b <0.01
Hematologic failure 9 (3.4) 5 (3.0) 4 (5.3) 0.66
Vasopressor use, n (%)
Dopamine use 95 (36.3) 64 (38.8) 49 (65.3)bc <0.01
Norepinephrine use 80 (30.4) 58 (35.2) 48 (64.0)bc <0.01
Intervention, n (%)
Ventilator use 221 (84.0) 143 (86.7) 69 (92.0) 0.21
New-onset dialysis 50 (19.0) 35 (21.2) 19 (25.3) 0.48
NeOAF new-onset atrial fibrillation, AF atrial fibrillation, SR sinus rhythm SOFA Sequential Organ Failure Assessment score, APACHE II Acute Physiology and Chronic
Health Evaluation II. aTotal organ failure is presented as median and interquartile range. bP < 0.05 vs. no NeOAF. cP < 0.05 vs. NeOAF to SR
Table 4 Therapeutic interventions in patients with sepsis and NeOAF
NeOAF patients (n = 240) P value
Overall (n = 240) NeOAF to SR (n = 165) NeOAF to AF (n = 75)
Pharmacological, n (%)
Amiodarone 80 (33.3) 52 (31.5) 28 (37.3) 0.38
Beta-blockers 88 (36.7) 67 (40.6) 21 (28.0) 0.06
Non-DHP CCBsa 66 (27.5) 47 (28.5) 19 (25.3) 0.61
Digoxin glycosides 27 (11.3) 15 (9.1) 12 (16.0) 0.12
Electrical cardioversion, n (%) 8 (3.3) 4 (2.4) 4 (5.3) 0.25
NeOAF new-onset atrial fibrillation, AF atrial fibrillation, SR sinus rhythm. aOnly indicates non-dihydropyridine calcium channel blockers (non-DHP CCBs)
Liu et al. Critical Care  (2016) 20:373 Page 5 of 9
hospital mortality. Baseline organ dysfunction, especially
neurologic, circulatory, hepatic, or renal dysfunction (which
are significant confounders for in-hospital mortality and
NeOAF status in patients with sepsis), was statistically
different in the three groups. Intriguingly, patients with
NeOAF in whom SR could not be restored (as NeOAF to
AF) has 2.22-fold higher risks of in-hospital mortality than
those in whom SR was restored (as NeOAF to SR) and
3.31-fold higher risks of in-hospital mortality than those
without NeOAF (as no NeOAF). In addition, in-hospital
mortality in patients with NeOAF and restored SR was not
statistically different compared with patients with no
NeOAF (P = 0.22, 95% CI = 0.79–2.83).
Previous research suggests that the prevalence of pre-
existing AF among hospitalized patients ranges from 2
to 15%. In our study, the prevalence of pre-existing AF
was 4.5%. Pre-existing AF was evaluated by previous
medical records and 12-lead ECG at admission, which
may underestimate the prevalence of AF in patients with
unrecognized paroxysmal AF. Moreover, the incidence
of NeOAF was 35.1% in this study, which is higher than
previous studies ranging from 10 to 46% [22]. It is prob-
ably due to higher disease severity, organ dysfunction and
frequent vasopressor use among the enrolled patients.
Association between sepsis and NeOAF
According to the mechanism of NeOAF proposed by most
studies, NeOAF in patients with sepsis is attributable to
sepsis-related inflammatory states. Basically, systemic
inflammation can alter atrial electrophysiology and struc-
tural substrates, leading to increased vulnerability to AF.
Complex inflammatory pathways affect myolysis, cardio-
myocyte apoptosis, and the activation of fibrotic pathways
through fibroblasts, transforming growth factor-β, and
matrix metalloproteases, contributing to structural re-
modeling of the atria [28, 29]. In addition, sepsis-related
micro-abscess formation and autonomic dysfunction may
be also responsible for the potential mechanisms for the
occurrence of NeOAF [30, 31].
The clinical management of patients with sepsis is also
associated with increased risks of NeOAF. Previous
studies suggest that fluid resuscitation and vasopressor
use in response to hypotension greatly contribute to the
development of NeOAF [24, 32]. Increased net positive
fluid resuscitation may result in an acute increase in left
ventricular end-diastolic pressure and subsequent left
atrial stretch, providing an anatomical substrate for the
occurrence of AF. Vasopressor agents, particularly those
with β-adrenergic effects, may also play a direct role in
triggering NeOAF [14, 18, 24, 33].
Serum CRP, an acute-phase reactant, has been consid-
ered a clinical indicator of inflammation. Hu et al. demon-
strated a positive relationship between elevated CRP and
the development and maintenance of AF [29]. AF is more
common in patients with high CRP than in those with low
CRP. Aviles et al. also reported that baseline CRP can be
used to predict the risk of AF in the general population
[34]. In patients with sepsis, Meierhenrich et al. demon-
strated continuous increments in CRP before the onset of
NeOAF [18]. These findings support the hypothesis that
the systemic inflammatory state can promote and per-
petuate AF. However, in our study, slightly higher CRP
was observed in patients without NeOAF than in those
with NeOAF. It was possibly due to CRP only being mea-
sured once at admission, the lack of series follow-up dur-
ing sepsis, or the development of NeOAF. Therefore, CRP
could be influenced by numerous confounding factors
during sepsis and we could not demonstrate the positive
association between CRP level and NeOAF in our study.
Hypothesis of rhythm control strategy in patients with
sepsis and NeOAF
The development of NeOAF could lead to deteriorated
hemodynamic status during sepsis. The occurrence of
Fig. 2 In-hospital mortality in patients with sepsis and different AF status.
NeOAF new-onset atrial fibrillation, AF atrial fibrillation, SR sinus rhythm
Table 5 Association between different AF status and in-hospital
mortality
Model OR 95% CI of OR P value
Model 1a
NeOAF to SR vs. no NeOAF 1.66 1.04–2.66 0.03
NeOAF to AF vs. no NeOAF 7.48 4.26–13.14 <0.01
NeOAF to AF vs. NeOAF to SR 4.50 2.52–8.04 <0.01
Model 2b
NeOAF to SR vs. no NeOAF 1.49 0.79–2.83 0.22
NeOAF to AF vs. no NeOAF 3.31 1.54–7.13 <0.01
NeOAF to AF vs. NeOAF to SR 2.22 1.02–4.83 0.045
NeOAF new-onset atrial fibrillation, AF atrial fibrillation, SR sinus rhythm, OR
odds ratio, CI confidence interval. aUnadjusted model. bAdjusted for age,
coronary artery disease, left ventricular ejection fraction, Sequential Organ
Failure Assessment score, neurologic failure, circulatory failure, hepatic failure,
renal failure, dopamine use, and norepinephrine use
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NeOAF makes the disease more complicated and makes
treatment during sepsis or septic shock more challenging
because of adverse cardiovascular effects including rapid
heart rate, irregular rhythm, loss of atrial systole, and neu-
rohormonal activation. In the acute phase, both tachycardia
and loss of atrial systole caused by AF could reduce the car-
diac output, further destablizing patients with sepsis. Subse-
quently, the burden of NeOAF in patients with sepsis may
result in acute heart failure [35, 36]. Moreover, atrial stasis
and sepsis-related coagulopathy could lead to systemic
embolization and an increased risk of ischemia stroke [19].
AF itself has been found to subsequently generate an
inflammatory response that further enhances atrial re-
modeling and perpetuates arrhythmia. Previous studies
have proposed that restoration and maintenance of SR
in patients with AF could result in gradually decreasing
CRP, indicating that AF initiates inflammation [37, 38].
Therefore, inflammation could promote AF and vice
versa. To stop the vicious cycle between inflammation
and AF, the early management of NeOAF by rhythm
control may be beneficial in patients with sepsis.
Our study highlighted that the restoration of SR in pa-
tients with sepsis and NeOAF led to more favorable
prognosis in comparison with failure to restore SR in
these patients. It is evident that restored SR in patients
with NeOAF could produce enhanced diastolic filling
and a rapid increase in left ventricular systolic perform-
ance among patients with NeOAF [39]. Meierhenrich et
al. reported that 23 out of 50 surgical patients with sep-
tic shock developed NeOAF [18]. They also demon-
strated that failure to restore SR was associated with
increased ICU mortality (71.4% versus 21.4%). Com-
pared to our study, we conducted a study in a more
modest-sized cohort of patients with non-surgical and
mixed sepsis and septic shock, and the disease severity
of sepsis was relatively lower in our study (SOFA score
7–9 versus 9–12). Consistently, we found that the in-
hospital mortality rate was significantly higher in the
NeOAF to AF group than in the NeOAF to SR group
(61.3% versus 26.1%). Restoration of SR appeared to be a
favorable prognostic marker of in-hospital mortality in
patients with sepsis and NeOAF, and this might have
further clinical implications for NeOAF surveillance and
treatment in this settings.
Treatment recommendation for NeOAF in patients with
sepsis
So far, recommendations for management of NeOAF in
patients with sepsis are dependent on observational
studies or expert opinions [40]. In principle, clinicians
should manage potentially reversible AF triggers includ-
ing electrolyte imbalances, rate-affected medication,
myocardial injury, and airway obstruction before starting
antiarrhythmic treatment.
Pharmacological options between a rate control and a
rhythm control strategy remain uncertain in patients with
sepsis and NeOAF. The rate control strategy tolerates AF,
but improves ventricular filling and avoids a tachycardia-
induced cardiomyopathy. It could be achieved by using
atrio-ventricular nodal blocking agents, such as beta-
blockers, non-DHP CCBs and digoxin. However, it should
be cautiously applied in patients with septic shock because
these agents have negative inotropic and vasodilatory
effects, probably leading to reduced cardiac output and
hypotension. A short-acting beta-blocker with esmolol
may be the first consideration in patients with septic
shock and NeOAF [41]. In the past, a rhythm control
compared with a rate control strategy has shown no sur-
vival benefit in non-critically ill patients [42]. Amiodarone
can slow nodal conduction and convert AF to sinus
rhythm. It has less negative inotropic effects compared
with beta-blockers and non-DHP CCB and may be safer
in patients with structural heart disease. Nevertheless,
current evidence is not strong enough to recommend that
amiodarone may improve the prognosis in patients with
sepsis and NeOAF [43, 44]. Moreover, as shown in Table 1,
the prevalence of previous treatment with beta-blockers
or CCBs was higher in the no NeOAF and NeOAF to SR
groups compared to the NEOAF to AF group. However,
evidence on NeOAF prophylaxis in patients with sepsis is
lacking. Further prospective, randomized studies are ne-
cessary to clarify the effects of beta-blockers or CCBs on
NeOAF prophylaxis in patients with sepsis.
Regarding anticoagulant use in patients with sepsis
and NeOAF, some studies have demonstrated that
NeOAF is associated with an increased risk of short-
term and long-term ischemic stroke, with threefold
higher stroke rates in patients with NeOAF than in those
without NeOAF during sepsis [19, 45]. However, the
benefit and risk of anticoagulant use during an acute
stage of sepsis remain unclear. Thus, anticoagulants can-
not be currently recommended as a cornerstone treat-
ment for sepsis-related NeOAF, and further large
prospective studies are warranted.
Study limitations
The present study had several limitations. First, it was a
single-center, retrospective, cohort study that relied on
accurate documentation, restricting the external validity
of our result. Second, several baseline characteristics of
the three groups were not equal. This might lead to bias
related to outcomes to a certain extent, despite statisti-
cally adjusting for these confounders. Third, we could
not determine which factors were the main factors for
the restoration of SR in patients with sepsis and NeOAF.
This could be attributed to the effect of antiarrhythmic
agents, improvement in sepsis-related inflammation, or
spontaneous recovery. Fourth, a fixed protocol was not
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used for the management of NeOAF. The pharmaco-
logical intervention was retrospectively recorded and
based on the clinicians’ orders under different clinical
conditions. We could not determine which medication
led to the therapeutic effect of SR restoration. Fifth, the
data on the use of anticoagulation were limited. Sixth,
data on the duration of vasopressor use, which may be a
confounder in the AF and mortality assessment, were
not available in the current study. Seventh, the associ-
ation between NeOAF to AF or no NeOAF and in-
hospital mortality was different in the two analysis
models. The discrepancy was due to the different defin-
ition of outcome in the logistic regression models
(event) and Cox proportional hazard models (time to
event). Finally, data on long-term follow up in the
NeOAF population, such as length of antiarrhythmic
therapy, new strokes, and anticoagulant therapy are not
obtainable.
Conclusion
In summary, NeOAF is prevalent in patients with sepsis and
is related to increased in-hospital mortality. We proposed
that successful restoration of SR in patients with sepsis and
NeOAF may offer a more favorable outcome than in those
in whom SR could not be restored. However, a larger, pro-
spective comparative study is needed to elucidate the clinical
implications between a rate control and a rhythm control
strategy in patients with sepsis and NeOAF.
Key messages
 New-onset atrial fibrillation (NeOAF) is prevalent
and associated with increased mortality in patients
with sepsis.
 It remains unclear whether restored sinus rhythm
(SR) of NeOAF leads to better outcomes and how to
suitably manage in patients with NeOAF.
 NeOAF with failure to restore SR (but not all
NeOAF) was an independent risk for in-hospital
mortality in patients with sepsis.
 Further prospective trials are warranted to elucidate
the clinical implications of a rate versus a rhythm
control strategy in patients with sepsis and NeOAF.
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